Stem cell therapies - K-STEMCELL

Drug Profile

Stem cell therapies - K-STEMCELL

Alternative Names: Adipose stem cell therapies - K-STEMCELL; Adult-derived stem cell therapies - K-STEMCELL; Astrostem; Autologous adipose stem cells - K-STEMCELL; Autologous Adipose Tissue derived MSCs Transplantation - K-STEMCELL; Cancerstem; Fat-derived stem cell therapies - K-STEMCELL; JointStem; Lipostem-DM; Lipostem-Femoran; Mesenchymal stem cell therapies - K-STEMCELL; RNL-JointStem; RNL-Vascostem; Vascostem

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator RNL BIO
  • Developer Asan Medical Center; K-STEMCELL
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Osteoarthritis
  • Phase I/II Femur head necrosis; Intervertebral disc degeneration; Spinal cord injuries; Thromboangiitis obliterans
  • Preclinical Alzheimer's disease; Cancer; Cerebral infarction; Diabetes mellitus; Fracture; Ischaemic heart disorders
  • No development reported Facial hemiatrophy; Liver disorders; Peripheral vascular disorders

Most Recent Events

  • 01 Dec 2016 Biostar completes a phase II/III trial in Osteoarthritis in South Korea (Intra-articular) (NCT02658344)
  • 28 Nov 2016 Nature Cell receives approval from US FDA to conduct phase I and phase II trials for the treatment of Alzheimer's disease
  • 01 Nov 2016 Biostar initiates a clinical trial for Osteoarthritis in South Korea (Intra-articular) (NCT03000712)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top